Alpha Tau Medical Ltd./$DRTS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
Ticker
$DRTS
Sector
Primary listing
Employees
125
Headquarters
Jerusalem, Israel
Website
DRTS Metrics
BasicAdvanced
$337M
-
-$0.48
1.00
-
Price and volume
Market cap
$337M
Beta
1
52-week high
$4.69
52-week low
$2.30
Average daily volume
64K
Financial strength
Current ratio
10.517
Quick ratio
9.772
Long term debt to equity
14.123
Total debt to equity
15.37
Interest coverage (TTM)
-121.82%
Profitability
EBITDA (TTM)
-36.445
Effective tax rate (TTM)
-0.47%
Management effectiveness
Return on assets (TTM)
-22.66%
Return on equity (TTM)
-43.83%
Valuation
Price to book
3.89
Price to tangible book (TTM)
3.89
Price to free cash flow (TTM)
-10.702
Free cash flow yield (TTM)
-9.34%
Free cash flow per share (TTM)
-0.37
Growth
Earnings per share change (TTM)
21.97%
3-year earnings per share growth (CAGR)
-13.08%
Bulls say / Bears say
Alpha Tau strengthened its balance sheet by raising $36.9 million in a registered direct offering with Oramed in April 2025, supporting its R&D and manufacturing operations. (Nasdaq)
As of June 30, 2025, Alpha Tau reported $83.3 million in cash and equivalents, up from $62.9 million at year-end 2024, providing more than two years of funding runway for clinical and commercial initiatives. (GlobeNewswire)
The FDA has issued four IDE approvals for Alpha DaRT, allowing pilot studies in pancreatic cancer and recurrent GBM, with patient enrollment and treatment planned for late 2025. (GlobeNewswire)
Alpha Tau’s operating loss rose to $18.8 million in H1 2025 from $17.5 million in H1 2024, reflecting increasing R&D and G&A costs that could hasten cash burn. (GlobeNewswire)
With Alpha DaRT’s U.S. trials still in early-stage pilot phases and the first patient enrollments not expected until Q3 and H2 2025, commercial revenues are still a long way off. (GlobeNewswire)
The $36.9 million April 2025 financing included warrants for further share issuance as part of a three-year service agreement, presenting a potential dilution risk for shareholders. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alpha Tau Medical Ltd. stock?
Alpha Tau Medical Ltd. (DRTS) has a market cap of $337M as of November 08, 2025.
What is the P/E ratio for Alpha Tau Medical Ltd. stock?
The price to earnings (P/E) ratio for Alpha Tau Medical Ltd. (DRTS) stock is 0 as of November 08, 2025.
Does Alpha Tau Medical Ltd. stock pay dividends?
No, Alpha Tau Medical Ltd. (DRTS) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next Alpha Tau Medical Ltd. dividend payment date?
Alpha Tau Medical Ltd. (DRTS) stock does not pay dividends to its shareholders.
What is the beta indicator for Alpha Tau Medical Ltd.?
Alpha Tau Medical Ltd. (DRTS) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.